LAG3 and metastatic melanoma: In the context of the recent approval of combined nivolumab and relatlimab (a LAG-3 inhibitor approved for unresectable or metastatic melanoma)12 our results demonstrating PD-1 increase and outsized LAG-3 induction from dual treatment may preliminarily indicate a therapeutic role for pembrolizumab and DPCP in multi-agent therapy with LAG-3 inhibitors which merits further investigation.